{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-053319","form_type":"8-K","ticker":"SSKN","cik":"0001051514","company_name":"STRATA Skin Sciences, Inc.","filed_at":"2023-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.046676+00:00","generated_at":"2026-06-08T01:56:29.652208+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"STRATA Skin Sciences Q3 revenue down 6% to $8.9M; suspends FY 2023 guidance","bullets":["Total revenues $8.9M vs $9.4M in Q3 2022 (-6.0%); global recurring rev $5.3M vs $5.8M.","Net loss $1.1M ($0.03 loss per share) vs $1.0M loss in Q3 2022.","Non-GAAP EBITDA improved to $1.0M from $0.6M; gross margin fell to 56% from 62%.","Company suspends FY 2023 guidance following management change effective Oct 31, 2023.","Dr. Dolev Rafaeli named CEO and Vice-Chairman, effective October 31, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-053319","json":"https://secwatch.observer/filing/0001140361-23-053319.json","markdown":"https://secwatch.observer/filing/0001140361-23-053319.md","text":"https://secwatch.observer/filing/0001140361-23-053319.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1051514/000114036123053319/0001140361-23-053319-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1051514/000114036123053319/ef20014656_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T01:56:29.652208+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"887239d0c36f20fe9c5c0b7ace671d349fd2c341","claim":"STRATA Skin Sciences, Inc. reported the third fiscal quarter ended September 30, 2023 results: revenue $8.9 million, net income Net loss for the third quarter of 2023 was $1.1 million, or a loss of $0.03 per basic and diluted common share, EPS $0.03 per basic and diluted common share.","evidence_excerpt":"conditions, today announced financial results for the third quarter ended September 30, 2023. Third Quarter 2023 and Recent Business Highlights: ● Total Revenues were $8.9 million compared to $9.4 million for the third quarter of 2022, a total decrease of 6.0%. ● Non-GAAP EBITDA improved to $1.0 million compared to $0.6 million for the third quarter of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1051514/000114036123053319/0001140361-23-053319-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third fiscal quarter ended September 30, 2023"},{"label":"Revenue","value":"$8.9 million"},{"label":"Net income","value":"Net loss for the third quarter of 2023 was $1.1 million, or a loss of $0.03 per basic and diluted common share"},{"label":"EPS","value":"$0.03 per basic and diluted common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}